Abstract
Maraviroc has been shown to be effective in patients harbouring CCR5-tropic HIV-1. While this CCR5 antagonist has initially been used in salvage therapy, its excellent safety profile makes it ideal for antiretroviral treatment simplification strategies in patients with suppressed plasma viraemia. The aim of this study was to compare HIV-1 tropism as detected in baseline plasma RNA and peripheral blood mononuclear cell (PBMC) DNA prior to first-line therapy and to analyse tropism evolution while on successful treatment.
Lingua originale | English |
---|---|
pagine (da-a) | N/A-N/A |
Rivista | Journal of Antimicrobial Chemotherapy |
DOI | |
Stato di pubblicazione | Pubblicato - 2013 |
Keywords
- HIV type 1
- V3
- genotype interpretation
- gp120